New developments in the treatment of postmenopausal breast cancer

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Tamoxifen has been the standard endocrine therapy for postmenopausal breast cancer.
• Newer agents, including third-generation aromatase inhibitors (AIs) and fulvestrant, offer alternatives with distinct mechanisms of action.
• Fulvestrant is an estrogen receptor antagonist without the partial agonist activity seen with tamoxifen.

Purpose of the Study:

• To review recent developments in endocrine therapy for postmenopausal breast cancer.
• To evaluate the role of third-generation aromatase inhibitors (anastrozole, letrozole, exemestane) and fulvestrant.
• To discuss the implications of new trial data for adjuvant treatment strategies.

Main Methods:

• Review of final results from the "Arimidex", Tamoxifen, Alone or in Combination (ATAC) trial.
• Analysis of recent switching studies involving anastrozole and exemestane.
• Discussion of current and future sequencing options for endocrine therapy.

Main Results:

• Final ATAC trial results (median follow-up >5 years) support the use of AIs in adjuvant therapy.
• Switching studies further strengthen the position of anastrozole and exemestane in early breast cancer treatment.
• Non-steroidal AIs are increasingly being incorporated earlier in treatment sequences.

Conclusions:

• Third-generation aromatase inhibitors are established as a key adjuvant treatment for hormone receptor-positive early breast cancer.
• The efficacy and safety profiles of these agents support their continued use and exploration in treatment sequencing.
• Future research will likely focus on optimizing the sequence and combination of endocrine therapies.